Hisamitsu Pharmaceutical Co. Inc
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP X… Read more
Hisamitsu Pharmaceutical Co. Inc (HPX) - Total Assets
Latest total assets as of August 2024: €350.48 Billion EUR
Based on the latest financial reports, Hisamitsu Pharmaceutical Co. Inc (HPX) holds total assets worth €350.48 Billion EUR as of August 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Hisamitsu Pharmaceutical Co. Inc - Total Assets Trend (2014–2025)
This chart illustrates how Hisamitsu Pharmaceutical Co. Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Hisamitsu Pharmaceutical Co. Inc - Asset Composition Analysis
Current Asset Composition (February 2025)
Hisamitsu Pharmaceutical Co. Inc's total assets of €350.48 Billion consist of 59.4% current assets and 40.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 33.4% |
| Accounts Receivable | €47.22 Billion | 13.8% |
| Inventory | €22.39 Billion | 6.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.68 Billion | 1.4% |
| Goodwill | €1.29 Billion | 0.4% |
Asset Composition Trend (2014–2025)
This chart illustrates how Hisamitsu Pharmaceutical Co. Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hisamitsu Pharmaceutical Co. Inc's current assets represent 59.4% of total assets in 2025, an increase from 55.2% in 2014.
- Cash Position: Cash and equivalents constituted 33.4% of total assets in 2025, up from 26.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 6.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 13.8% of total assets.
Hisamitsu Pharmaceutical Co. Inc Competitors by Total Assets
Key competitors of Hisamitsu Pharmaceutical Co. Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Hisamitsu Pharmaceutical Co. Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Hisamitsu Pharmaceutical Co. Inc generates 0.45x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Hisamitsu Pharmaceutical Co. Inc generates $6.34 in net profit.
Hisamitsu Pharmaceutical Co. Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.53 | 3.97 | 5.05 |
| Quick Ratio | 3.14 | 3.59 | 4.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €148.44 Billion | € 160.72 Billion | € 164.85 Billion |
Hisamitsu Pharmaceutical Co. Inc - Advanced Valuation Insights
This section examines the relationship between Hisamitsu Pharmaceutical Co. Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.56 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 4.3% |
| Total Assets | €343.07 Billion |
| Market Capitalization | $2.09 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hisamitsu Pharmaceutical Co. Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hisamitsu Pharmaceutical Co. Inc's assets grew by 4.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hisamitsu Pharmaceutical Co. Inc (2014–2025)
The table below shows the annual total assets of Hisamitsu Pharmaceutical Co. Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-02-28 | €343.07 Billion | +4.35% |
| 2024-02-29 | €328.78 Billion | +4.73% |
| 2023-02-28 | €313.92 Billion | +3.65% |
| 2022-02-28 | €302.86 Billion | +1.00% |
| 2021-02-28 | €299.86 Billion | -2.45% |
| 2020-02-29 | €307.40 Billion | +3.32% |
| 2019-02-28 | €297.51 Billion | -0.80% |
| 2018-02-28 | €299.91 Billion | +7.57% |
| 2017-02-28 | €278.82 Billion | -2.15% |
| 2016-02-29 | €284.95 Billion | -0.17% |
| 2015-02-28 | €285.44 Billion | +13.34% |
| 2014-02-28 | €251.85 Billion | -- |